GF
Therapeutic Areas
PDS Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PDS0101 (Versamune®-HPV) | HPV16-positive Head and Neck Cancer (Recurrent/Metastatic) | Phase 3 |
| PDS01ADC + Versamune® | 3rd Line Metastatic Cancer | Phase 2 |
| Versamune®-based Therapies | Prostate Cancer | Not Specified |
| Infectimune®-based Vaccines | Selected deadly infectious diseases | Preclinical/Research |
Leadership Team at PDS Biotechnology
FB
Frank Bedu-Addo, Ph.D.
Chief Executive Officer, Director
ST
Stephan Toutain
Chief Operating Officer
LB
Lars Boesgaard
Chief Financial Officer
GC
Gregory Conn, Ph.D.
Chief Scientific Officer
II
Ilian Iliev, Ph.D.
Director
OW
Otis W. Brawley, M.D.
Director